FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, alongside reduced-calorie diet and increased activity. Discuss it with the clinician managing your sleep apnea; do not stop PAP on your own.
A trial average is not an instruction to discontinue PAP.
The approval has a specific population
Tirzepatide is no longer only a weight-loss research story for people with obstructive sleep apnea. In December 2024, FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. The current product label retains that indication.[1] [2]
Each part of that description matters. It identifies the brand, the type and severity of apnea, and the presence of obesity. It does not mean that any snoring, poor sleep or daytime tiredness is an indication for this medicine. A symptom search and a documented sleep diagnosis are different starting points.
It also does not automatically extend the indication to every tirzepatide offer. Mounjaro and Zepbound share an ingredient, but product labeling remains specific. Our brand and indication comparison explains why an ingredient name alone can make an otherwise sensible comparison go wrong.
For a reader already receiving sleep-apnea care, the useful question is whether this option belongs in their existing treatment plan. For someone who suspects apnea, the next step is clinical evaluation rather than treating a medicine advertisement as a diagnosis.
Two trials, two PAP situations
SURMOUNT-OSA comprised two randomized, double-blind, placebo-controlled trials lasting 52 weeks. Both studied adults with obesity and moderate to severe obstructive sleep apnea. One enrolled people not using positive airway pressure at baseline; the other enrolled people already receiving PAP. Lilly funded the research.[3]
Keeping those groups separate helps interpret the finding. The study program included more than one care situation, but it did not randomize tirzepatide against PAP as competing treatments. “Studied in people using PAP” and “proven to replace PAP” are different claims.
| Trial context | Randomized comparison | What it does not establish |
|---|---|---|
| Not using PAP at baseline | Tirzepatide versus placebo | That medicine is preferable to starting PAP. |
| Using PAP at baseline | Tirzepatide versus placebo | That an individual can discontinue PAP. |
| Both groups followed for 52 weeks | Change in sleep-apnea measures | A guaranteed lifelong response. |
A trial’s structure is often more informative than the biggest number in its press coverage. It tells you which question was tested, what the comparator was and where a claim starts to exceed the experiment.
The brand and indication guide explains product distinctions. Our Form Health review examines the separate question of ongoing care.
Read the breathing result in events per hour
The primary outcome was change in the apnea-hypopnea index, or AHI: the number of apneas and hypopneas per hour of sleep. Mean AHI changes at week 52 were −25.3 with tirzepatide versus −5.3 with placebo in trial 1, and −29.3 versus −5.5 in trial 2. Estimated between-group differences were −20.0 and −23.8 events per hour respectively.[3]
The distinction between change and final level matters. A fall of 25 events per hour does not mean that the final AHI is 25, and it certainly does not mean every participant reached zero. To understand the remaining disease burden, the starting value and the later measurement both matter.
Likewise, the change in the placebo group belongs in the comparison. Quoting only the treatment group’s before-and-after improvement makes it harder to see what randomization contributed. A reader should look for the contrast between groups rather than assume every observed change was uniquely caused by the medicine.
These are average trial outcomes. They justify discussing a treatment option; they do not replace an individual reassessment. The right question at follow-up is what changed for the patient and how that affects their care plan, not whether their result exactly matches a published mean.
Improvement is not permission to abandon PAP
The FDA approval announcement notes that one trial included people using PAP and the other included people unable or unwilling to use it. FDA also describes the observed apnea improvement as likely related to weight reduction.[1]
Neither statement supplies a rule for stopping an existing device. If treatment changes weight, symptoms or sleep measurements, discuss reassessment with the sleep clinician. Do not decide that quieter snoring or feeling more rested is sufficient evidence to discontinue prescribed PAP.
It helps to ask in advance who will coordinate the two parts of care. A weight-management service may prescribe a medicine while a sleep practice manages PAP. Identify who reviews sleep results, who evaluates symptoms and how each receives relevant updates. Otherwise the patient may be left to reconcile separate advice without a shared plan.
The broader lesson is that new evidence can add an option without making established care obsolete. A medicine trial and a device-management decision involve related but distinct questions. Keeping them separate makes room for a careful treatment discussion instead of a false either-or choice.
Safety still belongs beside benefit
A sleep-apnea indication does not remove the medicine’s other considerations. Zepbound’s prescribing information contains a thyroid C-cell tumor boxed warning and contraindications involving medullary thyroid carcinoma or MEN 2, as well as warnings covering severe gastrointestinal reactions, pancreatitis and other risks. The clinician must review the full label and history.[2]
Ask how to report symptoms and whom to contact between scheduled visits. The practical quality of that arrangement is not measured by a trial’s average AHI result. If a service advertises this indication, it should still be able to explain the clinical assessment, follow-up and coordination it provides.
For help interpreting adverse-event percentages, read our side effects and dropout analysis. Having an event, stopping treatment and leaving a trial are different outcomes. A reassuring completion percentage is not a complete account of the treatment experience.
Make the coverage question specific
An approved indication and an insurance payment are separate decisions. Ask the plan what documentation it requires for the prescribed product and condition, which pharmacy route applies and what the patient will owe. Do not assume that a weight-management exclusion settles every apnea-related claim, or that an apnea diagnosis guarantees coverage.
Bring the written answer to the prescribing team. A complete quote should distinguish the medicine from visits, any required testing and ongoing sleep-apnea care. The cost worksheet provides a place to keep these components separate rather than burying them inside one monthly estimate.
Our provider comparison and Form Health review examine service arrangements, not individual eligibility for this indication. When narrowing options, ask directly whether the service can coordinate with the clinician managing your apnea and what records it needs before making a prescribing decision.
The research makes the conversation more concrete: a specific approved product, a defined population and randomized evidence for breathing outcomes. The next decision still requires the patient’s sleep diagnosis, existing treatment, clinical history and practical access to be considered together.